Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chih-Jen Yang

Showing results (141-150 of 191) with videos related to

Pageof 20
Sort By:
The Kaohsiung Journal of Medical Sciences|October 10, 2022
Real-world treatment pattern and prognostic factors of stage IV lung squamous cell carcinoma patientsEn-Chi Hsu, Kuan-Li Wu, Ying-Ming Tsai, et al.
The Kaohsiung Journal of Medical Sciences|September 26, 2025
Clinical Outcomes of Different Generation EGFR TKIs in Susceptible EGFR-Mutated Advanced Nonsmall-Cell Lung CancerChia-Yu Kuo, Tien-Chi Huang, Chih-Jen Yang, et al.
Plos One|August 1, 2015
Plasminogen Activator Inhibitor-2 Plays a Leading Prognostic Role among Protease Families in Non-Small Cell Lung CancerChia-Yi Su, Yu-Peng Liu, Chih-Jen Yang, et al.
Cancers|January 11, 2022
Salvage Therapy for Relapsed Malignant Pleural Mesothelioma: A Systematic Review and Network Meta-AnalysisYu-Chen Tsai, Hsiao-Ling Chen, Tai-Huang Lee, et al.
The Kaohsiung Journal of Medical Sciences|March 25, 2024
Clinical outcome of bevacizumab or ramucirumab combined with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors as the first line therapy in susceptible EGFR-mutated advanced non-small-cell lungChia-Yu Kuo, Ming-Ju Tsai, Jen-Yu Hung, et al.
Future Oncology (London, England)|June 19, 2026
Local consolidative therapy after EGFR-TKI response in advanced EGFR-mutant NSCLCChih-Jen Yang, Yu-Wei Liu, Min-Fang Chao, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 31, 2010
Lung cancer-derived galectin-1 mediates dendritic cell anergy through inhibitor of DNA binding 3/IL-10 signaling pathwayPo-Lin Kuo, Jen-Yu Hung, Shau-Ku Huang, et al.
BMC Cancer|May 4, 2021
Lower starting dose of afatinib for the treatment of metastatic lung adenocarcinoma harboring exon 21 and exon 19 mutationsYi-Chieh Chen, Ming-Ju Tsai, Mei-Hsuan Lee, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|April 29, 2023
Proteins Secreted by Lung Cancer Cells Induce the Onset of Proteinuria via Focal Adhesion Kinase Signaling in MiceSheng-Wen Niu, Chien-Hsing Wu, Hung-Chun Chen, et al.
Anticancer Research|January 30, 2026
Clinicopathologic Predictors of Outcome and Implications for Adjuvant Therapy in Pathologic Stage II Non-small Cell Lung CancerYi-Wen Shen, Tai-Huang Lee, Hui-Yang Hung, et al.
Pageof 20

Showing results (141-150 of 191) with videos related to

Sort By:
Pageof 20
The Kaohsiung Journal of Medical Sciences|October 10, 2022
Real-world treatment pattern and prognostic factors of stage IV lung squamous cell carcinoma patientsEn-Chi Hsu, Kuan-Li Wu, Ying-Ming Tsai, et al.
The Kaohsiung Journal of Medical Sciences|September 26, 2025
Clinical Outcomes of Different Generation EGFR TKIs in Susceptible EGFR-Mutated Advanced Nonsmall-Cell Lung CancerChia-Yu Kuo, Tien-Chi Huang, Chih-Jen Yang, et al.
Plos One|August 1, 2015
Plasminogen Activator Inhibitor-2 Plays a Leading Prognostic Role among Protease Families in Non-Small Cell Lung CancerChia-Yi Su, Yu-Peng Liu, Chih-Jen Yang, et al.
Cancers|January 11, 2022
Salvage Therapy for Relapsed Malignant Pleural Mesothelioma: A Systematic Review and Network Meta-AnalysisYu-Chen Tsai, Hsiao-Ling Chen, Tai-Huang Lee, et al.
The Kaohsiung Journal of Medical Sciences|March 25, 2024
Clinical outcome of bevacizumab or ramucirumab combined with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors as the first line therapy in susceptible EGFR-mutated advanced non-small-cell lungChia-Yu Kuo, Ming-Ju Tsai, Jen-Yu Hung, et al.
Future Oncology (London, England)|June 19, 2026
Local consolidative therapy after EGFR-TKI response in advanced EGFR-mutant NSCLCChih-Jen Yang, Yu-Wei Liu, Min-Fang Chao, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 31, 2010
Lung cancer-derived galectin-1 mediates dendritic cell anergy through inhibitor of DNA binding 3/IL-10 signaling pathwayPo-Lin Kuo, Jen-Yu Hung, Shau-Ku Huang, et al.
BMC Cancer|May 4, 2021
Lower starting dose of afatinib for the treatment of metastatic lung adenocarcinoma harboring exon 21 and exon 19 mutationsYi-Chieh Chen, Ming-Ju Tsai, Mei-Hsuan Lee, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|April 29, 2023
Proteins Secreted by Lung Cancer Cells Induce the Onset of Proteinuria via Focal Adhesion Kinase Signaling in MiceSheng-Wen Niu, Chien-Hsing Wu, Hung-Chun Chen, et al.
Anticancer Research|January 30, 2026
Clinicopathologic Predictors of Outcome and Implications for Adjuvant Therapy in Pathologic Stage II Non-small Cell Lung CancerYi-Wen Shen, Tai-Huang Lee, Hui-Yang Hung, et al.
Pageof 20